III期-话题@MedSci

#III期#

681篇内容 | 2806人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594747, encodeId=e9481594e4732, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎, objectType=article, longId=195329, objectId=e84519532957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e84519532957, replyNumber=0, likeNumber=20, createdTime=2020-06-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e84519532957, moduleTitle=诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e84519532957)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594746, encodeId=08b71594e460a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=抗体片段efgartigimod治疗重症肌无力：III期试验迎硕果！, objectType=article, longId=194860, objectId=254019486069, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=254019486069, replyNumber=0, likeNumber=71, createdTime=2020-05-29, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=254019486069, moduleTitle=抗体片段efgartigimod治疗重症肌无力：III期试验迎硕果！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=254019486069)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594745, encodeId=c8401594e4576, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=张伯礼：加快新冠病毒疫苗III期临床试验, objectType=article, longId=194542, objectId=0f3a194542ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f3a194542ed, replyNumber=0, likeNumber=79, createdTime=2020-05-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f3a194542ed, moduleTitle=张伯礼：加快新冠病毒疫苗III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f3a194542ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594743, encodeId=f52c1594e4381, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=抢位K药？百济神州PD-1联合化疗一线治疗晚期鳞状非小细胞肺癌III期数据公布, objectType=article, longId=194361, objectId=efad194361a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efad194361a2, replyNumber=0, likeNumber=52, createdTime=2020-05-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efad194361a2, moduleTitle=抢位K药？百济神州PD-1联合化疗一线治疗晚期鳞状非小细胞肺癌III期数据公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efad194361a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594744, encodeId=a52a1594e4440, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=江西首家III期肺癌多学科规范化诊疗中心成立, objectType=article, longId=194358, objectId=f3e51943580e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3e51943580e, replyNumber=0, likeNumber=81, createdTime=2020-05-20, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3e51943580e, moduleTitle=江西首家III期肺癌多学科规范化诊疗中心成立, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3e51943580e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594742, encodeId=c0b81594e4265, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, objectType=article, longId=194316, objectId=c1c619431626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1c619431626, replyNumber=0, likeNumber=15, createdTime=2020-05-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1c619431626, moduleTitle=诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1c619431626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594741, encodeId=799f1594e4178, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期临床：赛诺菲的CD38单抗Sarclisa显着降低了多发性骨髓瘤复发患者的死亡风险, objectType=article, longId=194121, objectId=ec9d1941215a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec9d1941215a, replyNumber=0, likeNumber=55, createdTime=2020-05-15, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec9d1941215a, moduleTitle=III期临床：赛诺菲的CD38单抗Sarclisa显着降低了多发性骨髓瘤复发患者的死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec9d1941215a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594740, encodeId=679c1594e4059, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Otezla（apremilast）治疗轻中度斑块型牛皮癣的III期ADVANCE研究：取得积极结果, objectType=article, longId=193626, objectId=9c621936262c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c621936262c, replyNumber=0, likeNumber=103, createdTime=2020-05-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c621936262c, moduleTitle=Otezla（apremilast）治疗轻中度斑块型牛皮癣的III期ADVANCE研究：取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c621936262c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594739, encodeId=6d891594e3957, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始, objectType=article, longId=193525, objectId=9a4819352542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a4819352542, replyNumber=0, likeNumber=16, createdTime=2020-05-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a4819352542, moduleTitle=AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a4819352542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594738, encodeId=91491594e3834, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=女性滴虫病的治疗：Solosec®（secnidazole）的III期临床取得积极结果, objectType=article, longId=193524, objectId=6f49193524a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f49193524a1, replyNumber=0, likeNumber=53, createdTime=2020-05-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f49193524a1, moduleTitle=女性滴虫病的治疗：Solosec®（secnidazole）的III期临床取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f49193524a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594737, encodeId=df371594e3750, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）, objectType=article, longId=193348, objectId=1c5c193348ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c5c193348ad, replyNumber=0, likeNumber=73, createdTime=2020-05-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c5c193348ad, moduleTitle=AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c5c193348ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594736, encodeId=6ff71594e3666, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=瑞德西韦治疗重症住院COVID-19患者III期临床数据公开, objectType=article, longId=193204, objectId=9f0e19320472, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f0e19320472, replyNumber=0, likeNumber=120, createdTime=2020-05-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f0e19320472, moduleTitle=瑞德西韦治疗重症住院COVID-19患者III期临床数据公开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f0e19320472)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594735, encodeId=485e1594e351c, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=AACR 2020：厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究), objectType=article, longId=193163, objectId=3f4219316311, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f4219316311, replyNumber=0, likeNumber=63, createdTime=2020-05-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f4219316311, moduleTitle=AACR 2020：厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f4219316311)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594734, encodeId=18d81594e3435, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=AACR 2020：Durvalumab治疗III期不可切除NSCLC的吸烟状态亚组分析, objectType=article, longId=193155, objectId=a1ad1931551a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1ad1931551a, replyNumber=0, likeNumber=60, createdTime=2020-05-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1ad1931551a, moduleTitle=AACR 2020：Durvalumab治疗III期不可切除NSCLC的吸烟状态亚组分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1ad1931551a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594733, encodeId=2d4a1594e33b0, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=失眠新药daridorexantIII期试验结果积极，显著改善睡眠质量, objectType=article, longId=192884, objectId=b6191928848c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6191928848c, replyNumber=0, likeNumber=76, createdTime=2020-04-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6191928848c, moduleTitle=失眠新药daridorexantIII期试验结果积极，显著改善睡眠质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6191928848c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594732, encodeId=1c6f1594e32c4, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Opdivo/Cabometyx组合疗法用于一线治疗晚期肾癌的III期临床实验成功, objectType=article, longId=192743, objectId=597a192e43e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597a192e43e8, replyNumber=0, likeNumber=97, createdTime=2020-04-24, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597a192e43e8, moduleTitle=Opdivo/Cabometyx组合疗法用于一线治疗晚期肾癌的III期临床实验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=597a192e43e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594731, encodeId=12ba1594e31ea, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Incyte启动JAK抑制剂芦可替尼治疗COVID-19相关细胞因子风暴III期研究, objectType=article, longId=192565, objectId=2ba3192565fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ba3192565fa, replyNumber=0, likeNumber=61, createdTime=2020-04-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ba3192565fa, moduleTitle=Incyte启动JAK抑制剂芦可替尼治疗COVID-19相关细胞因子风暴III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ba3192565fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594730, encodeId=03a11594e3071, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组, objectType=article, longId=192391, objectId=50af192391d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50af192391d8, replyNumber=0, likeNumber=52, createdTime=2020-04-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50af192391d8, moduleTitle=Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50af192391d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594729, encodeId=91a81594e2971, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期ADAURA试验：Tagrisso在EGFR突变型肺癌患者的辅助治疗中具有压倒性疗效, objectType=article, longId=192016, objectId=e03e1920168c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e03e1920168c, replyNumber=0, likeNumber=112, createdTime=2020-04-13, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e03e1920168c, moduleTitle=III期ADAURA试验：Tagrisso在EGFR突变型肺癌患者的辅助治疗中具有压倒性疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e03e1920168c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594728, encodeId=5f961594e28ac, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, objectType=article, longId=191868, objectId=b01e191868d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b01e191868d2, replyNumber=0, likeNumber=48, createdTime=2020-04-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b01e191868d2, moduleTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b01e191868d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎

2020-06-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

抗体片段efgartigimod治疗重症肌无力：III期试验迎硕果！

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

张伯礼：加快新冠病毒疫苗III期临床试验

2020-05-23

智智灵药 (审核中...)

前往app查看评论内容

#III期#

抢位K药？百济神州PD-1联合化疗一线治疗晚期鳞状非小细胞肺癌III期数据公布

2020-05-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

江西首家III期肺癌多学科规范化诊疗中心成立

2020-05-20

智智灵药 (审核中...)

前往app查看评论内容

#III期#

诺和诺德的GLP-1激动剂索马鲁肽（Semaglutide）治疗肥胖症，III期临床试验成功

2020-05-19

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期临床：赛诺菲的CD38单抗Sarclisa显着降低了多发性骨髓瘤复发患者的死亡风险

2020-05-15

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Otezla（apremilast）治疗轻中度斑块型牛皮癣的III期ADVANCE研究：取得积极结果

2020-05-08

智智灵药 (审核中...)

前往app查看评论内容

#III期#

AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始

2020-05-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

女性滴虫病的治疗：Solosec®（secnidazole）的III期临床取得积极结果

2020-05-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）

2020-05-03

智智灵药 (审核中...)

前往app查看评论内容

#III期#

瑞德西韦治疗重症住院COVID-19患者III期临床数据公开

2020-05-01

智智灵药 (审核中...)

前往app查看评论内容

#III期#

AACR 2020：厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究)

2020-05-01

智智灵药 (审核中...)

前往app查看评论内容

#III期#

AACR 2020：Durvalumab治疗III期不可切除NSCLC的吸烟状态亚组分析

2020-05-01

智智灵药 (审核中...)

前往app查看评论内容

#III期#

失眠新药daridorexantIII期试验结果积极，显著改善睡眠质量

2020-04-25

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Opdivo/Cabometyx组合疗法用于一线治疗晚期肾癌的III期临床实验成功

2020-04-24

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Incyte启动JAK抑制剂芦可替尼治疗COVID-19相关细胞因子风暴III期研究

2020-04-21

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组

2020-04-18

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期ADAURA试验：Tagrisso在EGFR突变型肺癌患者的辅助治疗中具有压倒性疗效

2020-04-13

智智灵药 (审核中...)

前往app查看评论内容

#III期#

OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准

2020-04-11

科室
- - 订阅+
  - 更多科室
工具
服务